drugset / Trial / NCT03831503
A Study of INO-A002 in Healthy Dengue Virus-naive Adults
Non-randomizedSequentialOpen-labelPrevention
Summary
Phase 1, open label, single center, dose escalation study to evaluate the safety, tolerability and pharmacokinetic profile of dMAb-ZK190 following delivery of INO-A002 with Hylenex® recombinant delivered IM followed by EP in healthy adult Dengue naïve volunteers ages 18-60 years.
Timeline
- Start
- 2019-02-07
- Primary completion
- 2022-10-03
- Completion
- 2022-10-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | INO-A002 | Unknown | 0.5 mg | Intramuscular |
| Subject | INO-A002 | Unknown | 1 mg | Intramuscular |
| Subject | INO-A002 | Unknown | 2 mg | Intramuscular |
| Subject | INO-A002 | Unknown | 4 mg | Intramuscular |
Indications
No indication recorded.